Previous 10 | Next 10 |
BASKING RIDGE, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today ann...
BASKING RIDGE, N.J., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today ann...
The following slide deck was published by Caladrius Biosciences, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Caladrius Biosciences, Inc. 2021 Q2 - Results - Earnings Call Presentation
Caladrius Biosciences, Inc. (CLBS) Q2 2021 Earnings Conference Call August 05, 2021 4:30 PM ET Company Participants John Menditto – Vice President-Investor Relations and Corporate Communications David Mazzo – President and Chief Executive Officer James Nisco – Vice Presid...
Caladrius Biosciences (NASDAQ:CLBS): Q2 GAAP EPS of -$0.10 beats by $0.04. Revenue of $43.29M (+138.1% Y/Y) Press Release For further details see: Caladrius Biosciences EPS beats by $0.04
BASKING RIDGE, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, provides a...
BASKING RIDGE, N.J., July 29, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today anno...
BASKING RIDGE, N.J., July 22, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today anno...
NeuroBo Pharmaceuticals (NRBO) +36%.Immunome (IMNM) +29% rallies 31% after antibody cocktail neutralizes Delta variant in pre-clinical testingMediWound (MDWD) +19% announces positive topline results from Phase 3 pediatric ctudy (CIDS) of nexoBrid for eschar removal of seve...
Caladrius Biosciences (CLBS) announces that the FDA has authorized its investigational new drug ((IND)) application for the study of CLBS201, a CD34+ cell therapy for the treatment of diabetic kidney disease ((DKD)). “We plan to initiate a phase 1/2 proof-of-concept study of CLBS201 wi...
News, Short Squeeze, Breakout and More Instantly...
Caladrius Biosciences Inc. Company Name:
CLBS Stock Symbol:
NASDAQ Market:
Caladrius Biosciences Inc. Website:
BASKING RIDGE, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), announced today that, based upon the final vote count certified by the independent inspector of elections for the annual meeting of ...
NEW YORK, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Virtual Investor Conference to be held on September 15 th . Individual investors, institutional ...
BASKING RIDGE, N.J., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, today announced tha...